Spots Global Cancer Trial Database for cutaneous lymphoma
Every month we try and update this database with for cutaneous lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas | NCT04520529 | Cutaneous Lymph... | Biologic Sample... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies | NCT00629473 | Advanced Cancer | NPI-0052 on Day... NPI-0052 on Day... Dexamethasone | 18 Years - | Celgene | |
| Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | NCT01556828 | Cutaneous Lymph... Other Skin Diso... Mycosis Fungoid... Cutaneous T-cel... | 18 Years - | Stanford University | ||
| T-VEC in Non-melanoma Skin Cancer | NCT03458117 | Non-melanoma Sk... Basal Cell Carc... Squamous Cell C... Cutaneous Lymph... Merkel Cell Car... | Talimogene Lahe... | 18 Years - | University of Zurich | |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas | NCT03192202 | Lymphoma, T-Cel... | AFM13 | 18 Years - | Columbia University | |
| Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | NCT01187446 | Cutaneous Lymph... Cutaneous T-cel... | Total skin elec... Vorinostat | 18 Years - | Stanford University | |
| T-VEC in Non-melanoma Skin Cancer | NCT03458117 | Non-melanoma Sk... Basal Cell Carc... Squamous Cell C... Cutaneous Lymph... Merkel Cell Car... | Talimogene Lahe... | 18 Years - | University of Zurich | |
| Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | NCT01187446 | Cutaneous Lymph... Cutaneous T-cel... | Total skin elec... Vorinostat | 18 Years - | Stanford University | |
| ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells | NCT00400556 | Multiple Myelom... Cutaneous Lymph... | ATRA plus G-CSF... | 18 Years - 70 Years | Peter MacCallum Cancer Centre, Australia | |
| Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | NCT01187446 | Cutaneous Lymph... Cutaneous T-cel... | Total skin elec... Vorinostat | 18 Years - | Stanford University | |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | NCT01396070 | Non-Hodgkin Lym... Cutaneous Lymph... Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Brentuximab ved... | 18 Years - | Stanford University | |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | NCT01396070 | Non-Hodgkin Lym... Cutaneous Lymph... Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Brentuximab ved... | 18 Years - | Stanford University | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas | NCT04520529 | Cutaneous Lymph... | Biologic Sample... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas | NCT04520529 | Cutaneous Lymph... | Biologic Sample... | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
